Haesuk Park1, Xinyi Jiang1, Hyun Jin Song1, Vincent Lo Re2, Lindsey M Childs-Kean3, Wei-Hsuan Lo-Ciganic1, Robert L Cook4, David R Nelson4. 1. Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, FL. 2. Division of Infectious Diseases, Department of Medicine and Center for Clinical Epidemiology and Biostatistics, Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. 3. Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, FL. 4. Department of Medicine, University of Florida, Gainesville, FL.
Abstract
BACKGROUND AND AIMS: Our aim was to evaluate the impact of direct-acting antivirals (DAAs) on decompensated cirrhosis (DCC) and HCC in patients with chronic HCV and substance use disorder (SUD) compared with those without an SUD. APPROACH AND RESULTS: This retrospective cohort study used the MarketScan database (2013-2018) to identify 29,228 patients with chronic HCV, where 22% (n = 6,385) had ≥1 SUD diagnosis. The inverse probability of treatment weighted multivariable Cox proportional hazard models were used to compare the risk of developing DCC and HCC. Among the those who were noncirrhotic, treatment reduced the DCC risk among SUD (adjusted hazard ratio [aHR] 0.13; 95% CI, 0.06-0.30) and non-SUD (aHR 0.11; 95% CI, 0.07-0.18), whereas the risk for HCC was not reduced for the SUD group (aHR 0.91; 95% CI, 0.33-2.48). For those with cirrhosis, compared with patients who were untreated, treatment reduced the HCC risk among SUD (aHR, 0.33; 95% CI, 0.13-0.88) and non-SUD (aHR, 0.40; 95% CI, 0.25-0.65), whereas the risk for DCC was not reduced for the SUD group (aHR, 0.64; 95% CI, 0.37-1.13). Among patients with cirrhosis who were untreated, the SUD group had a higher risk of DCC (aHR, 1.52; 95% CI, 1.03-2.24) and HCC (aHR, 1.69; 95% CI, 1.05-2.72) compared with non-SUD group. CONCLUSIONS: Among the HCV SUD group, DAA treatment reduced the risk of DCC but not HCC for those who were noncirrhotic, whereas DAA treatment reduced the risk of HCC but not DCC for those with cirrhosis. Among the nontreated, patients with an SUD had a significantly higher risk of DCC and HCC compared with those without an SUD. Thus, DAA treatment should be considered for all patients with HCV and an SUD while also addressing the SUD.
BACKGROUND AND AIMS: Our aim was to evaluate the impact of direct-acting antivirals (DAAs) on decompensated cirrhosis (DCC) and HCC in patients with chronic HCV and substance use disorder (SUD) compared with those without an SUD. APPROACH AND RESULTS: This retrospective cohort study used the MarketScan database (2013-2018) to identify 29,228 patients with chronic HCV, where 22% (n = 6,385) had ≥1 SUD diagnosis. The inverse probability of treatment weighted multivariable Cox proportional hazard models were used to compare the risk of developing DCC and HCC. Among the those who were noncirrhotic, treatment reduced the DCC risk among SUD (adjusted hazard ratio [aHR] 0.13; 95% CI, 0.06-0.30) and non-SUD (aHR 0.11; 95% CI, 0.07-0.18), whereas the risk for HCC was not reduced for the SUD group (aHR 0.91; 95% CI, 0.33-2.48). For those with cirrhosis, compared with patients who were untreated, treatment reduced the HCC risk among SUD (aHR, 0.33; 95% CI, 0.13-0.88) and non-SUD (aHR, 0.40; 95% CI, 0.25-0.65), whereas the risk for DCC was not reduced for the SUD group (aHR, 0.64; 95% CI, 0.37-1.13). Among patients with cirrhosis who were untreated, the SUD group had a higher risk of DCC (aHR, 1.52; 95% CI, 1.03-2.24) and HCC (aHR, 1.69; 95% CI, 1.05-2.72) compared with non-SUD group. CONCLUSIONS: Among the HCV SUD group, DAA treatment reduced the risk of DCC but not HCC for those who were noncirrhotic, whereas DAA treatment reduced the risk of HCC but not DCC for those with cirrhosis. Among the nontreated, patients with an SUD had a significantly higher risk of DCC and HCC compared with those without an SUD. Thus, DAA treatment should be considered for all patients with HCV and an SUD while also addressing the SUD.
Authors: Jason Grebely; Gail V Matthews; Margaret Hellard; David Shaw; Ingrid van Beek; Kathy Petoumenos; Maryam Alavi; Barbara Yeung; Paul S Haber; Andrew R Lloyd; John M Kaldor; Gregory J Dore Journal: J Hepatol Date: 2010-11-23 Impact factor: 25.083
Authors: Douglas K Owens; Karina W Davidson; Alex H Krist; Michael J Barry; Michael Cabana; Aaron B Caughey; Katrina Donahue; Chyke A Doubeni; John W Epling; Martha Kubik; Gbenga Ogedegbe; Lori Pbert; Michael Silverstein; Melissa A Simon; Chien-Wen Tseng; John B Wong Journal: JAMA Date: 2020-03-10 Impact factor: 56.272
Authors: Mamta K Jain; Mae Thamer; George Therapondos; Mitchell L Shiffman; Onkar Kshirsagar; Christopher Clark; Robert J Wong Journal: Hepatology Date: 2018-12-18 Impact factor: 17.425
Authors: Oluwaseun Falade-Nwulia; Catalina Suarez-Cuervo; David R Nelson; Michael W Fried; Jodi B Segal; Mark S Sulkowski Journal: Ann Intern Med Date: 2017-03-21 Impact factor: 25.391
Authors: Albert Do; Yash Mittal; AnnMarie Liapakis; Elizabeth Cohen; Hong Chau; Claudia Bertuccio; Dana Sapir; Jessica Wright; Carol Eggers; Kristine Drozd; Maria Ciarleglio; Yanhong Deng; Joseph K Lim Journal: PLoS One Date: 2015-08-27 Impact factor: 3.240
Authors: Mei Lu; Wadih Chacra; David Rabin; Loralee B Rupp; Sheri Trudeau; Jia Li; Stuart C Gordon Journal: Clin Epidemiol Date: 2017-07-12 Impact factor: 4.790
Authors: Xinyi Jiang; Scott Martin Vouri; Vakaramoko Diaby; Weihsuan Lo-Ciganic; Robert Parker; Haesuk Park Journal: J Manag Care Spec Pharm Date: 2021-10
Authors: Xinyi Jiang; Robert L Parker; Scott Martin Vouri; Weihsuan Lo-Ciganic; Vakaramoko Diaby; Linda Henry; Haesuk Park Journal: Am J Prev Med Date: 2021-06-29 Impact factor: 6.604